Medpal AI plc
MedPal AI plc is a UK-based (England & Wales) AIM-listed company developing a vertically integrated, AI-powered digital health platform combining an AI wellness app, human-validated prescribing, a proprietary clinical triage engine, and licensed robotic pharmacy dispensing and delivery infrastructure. The Company was admitted to trading on AIM on 26 August 2025, five days before the FY2025 year end, and was pre-revenue throughout the financial year, with its first pharmacy/NHS contract and dispensing revenue only commencing after the year end. FY2025 was described by the Directors as an investment/formative phase focused on technology development, regulatory preparation and IPO execution.
FY2025 in sixty seconds
year to 31 Aug 2025 · approved 27 Feb 2026 · 55 pages · Companies House
MedPal AI plc is building an online health and pharmacy service driven by artificial intelligence. It joined the AIM stock market on 26 August 2025, five days before its year end, and earned no revenue in the year to 31 August 2025, the same as the year before. Its loss grew to £4.0m, from £14k.
The loss includes £1,843,198 of one-off costs of joining the stock market. The report also records a £2,331,238 charge, which used no cash, for share options and warrants given to directors and advisers around the listing. Spending on marketing and professional advisers also rose.
The company ended the year with £1.5m in cash, up from £253, and no borrowings. It raised £2.4m by selling new shares and paid no dividend. Management says its pharmacy began bringing in revenue of over £350,000 a month after the year end, and it will keep investing to grow. The auditor flagged real doubt, called a material uncertainty, over whether the company can keep going, as it relies on raising more money.
No revenue generated in FY2025 (2024: £nil); Company was pre-revenue throughout the period, focused on platform build and regulatory readiness
"The Company generated no revenue during the year ended 31 August 2025 (2024: £0)."
page 42One-off IPO/listing costs
Costs associated with the listing of £1,843,198 recognised separately from administrative expenses in the operating loss for FY2025 (2024: £nil)
page 29"In just six months since AIM admission, we have built and activated a fully operational, vertically integrated platform that is already generating substantial and growing monthly pharmacy revenue... the Company has created an outstanding foundation for scalable, capital-efficient growth."
page 5No dividend has been paid during the year (2024: £Nil), nor do the Directors recommend payment of a final dividend
page 122 years on one page · FY2024–FY2025
| Line | FY202408/24 | FY202508/25 |
|---|---|---|
| Revenue | ||
| Operating profit | ||
| Profit for the year | ||
| Basic EPS | ||
| Dividend per share | ||
| Free cash flow | ||
| Net debt (negative = net cash) | ||
| Shares in issue |
GBP millions, negatives in brackets. Per-share lines in pence. Share counts in millions. Margins and returns as percentages, calculated from the filed figures. later is what a following report restated the figure to; vs is a second reading that disagrees. The figure shown is the one the original filing printed, and both readings are kept. Click any figure: opens the report page it was read from, highlighted; shows how it was calculated.
Nothing restated
Nothing to compare yet: that takes a second report, which prints the first year's figures again.